What is it about?

Abrocitinib now has regulatory approval for the treatment of atopic dermatitis (AD), however it is not approved for alopecia areata (AA). We report two patients with severe AD and co-morbid alopecia areata, who achieved complete remission of their chronic AA with abrocitinib.

Featured Image

Why is it important?

To our knowledge these are the first reported cases of chronic severe alopecia areata demonstrating complete remission whilst being treated with abrocitinib. The demonstrated concurrent efficacy of abrocitinib in both AA and AD indicates the potential role of JAK1 in the pathogenesis of AA and the application of JAK 1 inhibitors in the treatment of AA.

Perspectives

This is an exciting time for emerging treatments in AA with the targeted research and development of Janus Kinase (JAK) Inhibitors. Achieving remission of chronic AA with abrocitinib provides further insight and supports the case for further targeted research within this (JAK 1 inhibition and AA) space.

Michaela Bennett
Sinclair Dermatology

Read the Original

This page is a summary of: Successful treatment of chronic severe alopecia areata with abrocitinib, Australasian Journal of Dermatology, April 2022, Wiley, DOI: 10.1111/ajd.13836.
You can read the full text:

Read

Contributors

The following have contributed to this page